Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
NCT07076407 is registered in ClinicalTrials.gov with Xenon Pharmaceuticals Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
- Lead sponsor
- Xenon Pharmaceuticals Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- July 8, 2025
- Completion date
- July 31, 2027
- Enrollment
- 450 (estimated)
- Sites
- 50
Conditions
As the registry lists them; a condition with its own page is linked.